相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Topoisomerase II poisons inhibit vertebrate DNA replication through distinct mechanisms
Sabrina X. Van Ravenstein et al.
EMBO JOURNAL (2022)
Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy
Ying Ma et al.
MOLECULAR BIOLOGY REPORTS (2021)
Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors
Evgeny Kiselev et al.
DNA REPAIR (2020)
SCFβ-TrCP-mediated degradation of TOP2β promotes cancer cell survival in response to chemotherapeutic drugs targeting topoisomerase II
Jianfeng Shu et al.
ONCOGENESIS (2020)
Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway
Mingjing Shen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity
Andres Canela et al.
MOLECULAR CELL (2019)
ATM in DNA repair in cancer
Mei Hua Jin et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Topoisomerases as anticancer targets
Justine L. Delgado et al.
BIOCHEMICAL JOURNAL (2018)
Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes
Ka Cheong Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor
Xiaoyu Chen et al.
CELL CYCLE (2018)
Recent developments in topoisomerase-targeted cancer chemotherapy
Kirk E. Hevener et al.
ACTA PHARMACEUTICA SINICA B (2018)
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Andrew N. Blackford et al.
MOLECULAR CELL (2017)
ZATT (ZNF451)-mediated resolution of topoisomerase 2 DNA-protein cross-links
Matthew J. Schellenberg et al.
SCIENCE (2017)
ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells
Cyril Ronco et al.
MEDCHEMCOMM (2017)
Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II
Ka C. Lee et al.
BIOCHEMICAL PHARMACOLOGY (2016)
ATM Mutations in Cancer: Therapeutic Implications
Michael Choi et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
Yves Pommier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
A critical role for topoisomerase IIb and DNA double strand breaks in transcription
Stuart K. Calderwood
TRANSCRIPTION-AUSTIN (2016)
Oxidized ATM promotes abnormal proliferation of breast CAFs through maintaining intracellular redox homeostasis and activating the PI3K-AKT, MEK-ERK, and Wnt-β-catenin signaling pathways
Shifu Tang et al.
CELL CYCLE (2015)
ATM and ATR as therapeutic targets in cancer
Anika Maria Weber et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition
Ronan Russell et al.
NATURE COMMUNICATIONS (2015)
ATM kinase sustains HER2 tumorigenicity in breast cancer
Venturina Stagni et al.
NATURE COMMUNICATIONS (2015)
Topoisomerase II and leukemia
MaryJean Pendleton et al.
BONE MARROW NICHE, STEM CELLS, AND LEUKEMIA: IMPACT OF DRUGS, CHEMICALS, AND THE ENVIRONMENT (2014)
Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2.DNA and Top2.RNA Covalent Complexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2)
Rui Gao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
ATM signalling and cancer
C. A. Cremona et al.
ONCOGENE (2014)
Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance
Esra Kaplan et al.
BIOMEDICINE & PHARMACOTHERAPY (2012)
Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?
Ian G. Cowell et al.
CELL CYCLE (2012)
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang et al.
NATURE MEDICINE (2012)
Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity
Ian G. Cowell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents
Ian G. Cowell et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2012)
Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs
Wang Chen et al.
DRUG DISCOVERIES AND THERAPEUTICS (2012)
Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts
Tooba A. Cheema et al.
CLINICAL CANCER RESEARCH (2011)
An overview of the visualisation and quantitation of low and high MW DNA adducts using the trapped in agarose DNA immunostaining (TARDIS) assay
Ian G. Cowell et al.
MUTAGENESIS (2011)
All tangled up: how cells direct, manage and exploit topoisomerase function
Seychelle M. Vos et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion
Sarah E. Golding et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Targeting DNA topoisomerase II in cancer chemotherapy
John L. Nitiss
NATURE REVIEWS CANCER (2009)
Topoisomerase levels determine chemotherapy response in vitro and in vivo
Darren J. Burgess et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Topoisomerase IIβ-Mediated DNA double-strand breaks:: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane
Yi Lisa Lyu et al.
CANCER RESEARCH (2007)
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
Anna M. Azarova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A protease pathway for the repair of topoisomerase II-DNA covalent complexes
Ailing Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The comet assay: a method to measure DNA damage in individual cells
Peggy L. Olive et al.
NATURE PROTOCOLS (2006)
A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia
E Willmore et al.
BLOOD (2004)
分享论文
